<SEC-DOCUMENT>0000950123-17-011181.txt : 20180223
<SEC-HEADER>0000950123-17-011181.hdr.sgml : 20180223
<ACCEPTANCE-DATETIME>20171201172816
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-17-011181
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20171201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		501 BOYLSTON STREET
		STREET 2:		SUITE 6102
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		501 BOYLSTON STREET
		STREET 2:		SUITE 6102
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRSLTR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">December 1, 2017 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dorrie Yale </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suzanne Hayes </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare and Insurance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation
Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street,
N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"><B>resTORbio, Inc. </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Confidentially Submitted on October&nbsp;27, 2017 </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CIK No.&nbsp;0001720580 </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ms.&nbsp;Yale: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On behalf of our client, resTORbio, Inc. (the &#147;<B>Company</B>&#148;), we are responding to the comments from the Staff (the
&#147;<B>Staff</B>&#148;) of the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) relating to the Company&#146;s confidential draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;Draft
Registration <B>Statement</B>&#148;) contained in the Staff&#146;s letter dated November&nbsp;22, 2017 (the &#147;<B>Comment Letter</B>&#148;). In response to the comments set forth in the Comment Letter, the Company has revised the Draft
Registration Statement and is confidentially submitting a revised draft of the Draft Registration Statement (the &#147;<B>Amended DRS</B>&#148;) together with this response letter. The Amended DRS also contains certain additional updates and
revisions. We are also sending, under separate cover, a copy of the Amended DRS (including exhibits) and four marked copies of the Amended DRS showing the changes to the Draft Registration Statement confidentially submitted on October&nbsp;27, 2017.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Set forth below are the Company&#146;s responses to the Staff&#146;s comments in the Comment Letter. The responses and information below
are based on information provided to us by the Company. For convenience, the Staff&#146;s comments are repeated below in italics, followed by the Company&#146;s response to the comments as well as a summary of the responsive actions taken. We have
included page numbers to refer to the location in the Amended DRS submitted herewith where the revised language addressing a particular comment appears. Capitalized terms used but not defined herein are used herein as defined in the Amended DRS.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Draft Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Summary, page 1 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>We note your statements that you were <FONT STYLE="white-space:nowrap">co-founded</FONT> by PureTech Health
LLC, which appears to be affiliated with PureTech Health plc, a public company listed on the London Stock Exchange. PureTech Health plc&#146;s publicly available investor documents refer to you as a subsidiary, and its</I>
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<I>website includes RTB101 in its pipeline of products. If correct, please revise your disclosure throughout the prospectus to clarify your current subsidiary relationship with PureTech Health
plc, any services PureTech provides to you, and disclose the expected percentage ownership PureTech Health will have in you following the offering and discuss all potential conflicts of interest</I>. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it does not believe that it is currently a subsidiary of PureTech Health, nor will it be a
subsidiary of PureTech Health following the proposed public offering because the Company does not believe PureTech Health is an affiliate that controls the Company, directly or indirectly through one or more intermediaries. Specifically, following
the closing of the Company&#146;s Series B preferred stock financing, the percentage ownership held by PureTech Health decreased to approximately 44% and, based on current expectations of the size of the proposed public offering, such percentage is
expected to decrease further to approximately 35% following the consummation of the proposed public offering. In connection with the Company&#146;s Series B preferred stock financing, the Company obtained investments from several large and
sophisticated institutional investors, each with its own interests, one of which have appointed a representative to the Company&#146;s board of directors. Concurrently, Bharatt Chowrira, an appointee of PureTech Health who previously served on the
Company&#146;s board of directors, has since resigned his directorship. The Company believes that the holdings of such stockholders and their participation on the Company&#146;s board of directors mitigate the influence that PureTech Health may have
over the Company. In addition, in connection with the proposed public offering, the Company intends to appoint three additional members of its board of directors that are affiliated neither with management of the Company nor its existing investors.
After giving effect to these changes to the Company&#146;s board of directors, its membership will consist of the Company&#146;s chief executive officer, two representatives of PureTech Health, one representative of another existing investor in the
Company, and three outside directors. The Company additionally advises the Staff that while PureTech Health is a founder of the Company and in that capacity has historically provided us with strategic medical, clinical and scientific advice, in
addition to sharing certain administrative resources and offices as described in the Amended DRS, the Company has started to transition these functions to its internal personnel and expects to continue to expand its internal organization in
connection with the proposed public offering. For the foregoing reasons, the Company respectfully submits to the Staff that it should not be viewed as a subsidiary of PureTech Health and should instead be viewed as a company in which strategic
investors, of which PureTech Health is one, hold ownership interests. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please limit the summary discussion of your results to whether the product candidate met the primary endpoints and a description of the primary endpoints. The discussion of
<FONT STYLE="white-space:nowrap">p-values</FONT> is more appropriate for the Business discussion, where you should also discuss how the values relate to the FDA&#146;s evidentiary standards of efficacy.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised page 1 in response to the Staff&#146;s comment. The Company supplementally
directs the Staff&#146;s attention to page 109 in which the Company explains that <FONT STYLE="white-space:nowrap">p-values</FONT> of less than 0.05 are considered statistically significant for purposes of evaluating its clinical trial results. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please remove the last row in your product pipeline table here and in the Business section since you have not yet identified a product candidate and indication and it is therefore premature to include it in the
pipeline table.</I> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised pages 2 and 101 in
response to the Staff&#146;s comment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Implications of Being an Emerging Growth Company, page 5 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in
reliance on Section</I><I></I><I>&nbsp;5(d) of the Securities Act, whether or not they retain copies of the communications.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company acknowledges the Staff&#146;s comment. The Company advises the Staff that the Company has supplementally provided
the Staff under separate cover with a copy of the presentation that the Company intends to use in testing the waters meetings with qualified institutional buyers or institutional accredited investors. The Company further advises the Staff that it
will supplementally provide the Staff with copies of any additional written communications of the type referenced in the Staff&#146;s comment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Use of
Proceeds, page 76 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please revise your disclosure to clarify whether you expect to be able to complete each of the identified uses with the proceeds from the offering and your other available assets. If you do not, please clarify your
expectations with respect to progress towards completion of the stated uses.</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the
Staff that it has revised page 76 in response to the Staff&#146;s comment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Critical Accounting Polices and Estimates </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Determination of Estimated Offering Price, page 93 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"><I>Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent
valuations of your common stock leading up to the IPO and the estimated offering price. This information will help facilitate our review of your accounting for equity issuances including stock compensation and beneficial conversion features.</I>
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company acknowledges the Staff&#146;s comment. Once an estimated price range has been determined, the
Company will supplementally provide the Staff with an analysis explaining how the Company determined the fair value of the common stock underlying the Company&#146;s equity issuances and the reasons for the difference between the most recent
valuations of its common shares leading up to the IPO and the estimated offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Our TORC1 Program, page 107 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please revise your narrative explanation of the figure on page 107 to clarify what the figure is designed to depict. Currently, it appears to state that RTB101 monotherapy can inhibit phosphorylation of S6K and
4EBP1, and that RTB101 in combination with everolimus may completely inhibit Ulk1. However, the figure appears to indicate that 42BP1 and Ulk1 activity increase as a result of the treatments.</I> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised page 107 in response to
the Staff&#146;s comment. The Company supplementally advises the Staff that RTB101 alone or in combination with everolimus is designed to inhibit phosphorylation of multiple downstream signaling nodes of TORC1. However, the arrows in the figure on
page 107 is designed to illustrate the <I>effect</I> of such inhibition of phosphorylation. Specifically, decreased phosphorylation of S6K results in decreased activity of that node, while decreased phosphorylation of 4EBP1 and Ulk1 results in
increased activity of those nodes. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please expand your narrative disclosure regarding the figures at the top of page 111 to further explain how they demonstrate that your product candidate may enhance innate immunity and provide the <FONT
STYLE="white-space:nowrap">p-values.</FONT></I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised page 111
in response to the Staff&#146;s comment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Intellectual Property, page 116 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please clarify the statement in the carryover paragraph on page 117 that intellectual property rights not controlled by Novartis as of the effective date are not included in the license to identify the referenced
intellectual property rights, explain whether such rights relate to your product candidates and if yes, whether you expect not having a license to such rights to have a material effect on your business.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised pages 116 and 177 in response to the Staff&#146;s comment and removed the
reference to intellectual property rights not included in the license agreement. The Company does not believe the absence of a license to such rights will have a material effect on its business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management, page 137 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"><I>We note that John McCabe is your Vice President, Finance and that he is indicated in the registration statement to be your principal financial and accounting officer. However, we also note that on your website, you
indicate that Landen Williams is your interim chief financial officer. Please revise or explain.</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The
Company advises the Staff that following Mr.&nbsp;McCabe&#146;s appointment as the Company&#146;s Vice President, Finance, Mr.&nbsp;Williams relinquished his role as interim CFO, and Mr.&nbsp;McCabe took over as the Company&#146;s principal
financial and accounting officer. The Company&#146;s website has been updated to reflect these changes in management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Transactions with Related
Persons, page 156 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please disclose the approximate value of the transaction in which you issued shares to PureTech Health in exchange for the founding business services.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised page 156 in response to the Staff&#146;s comment. The Company
supplementally advises the Staff that, as disclosed on page 155, such shares were issued as founder shares to PureTech Health at par value, the fair market value of such shares at the time of their issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please revise the discussion of your Investors&#146; Rights Agreement to identify the 5% stockholders, entities affiliated with your directors and these directors.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised pages 156 and 157 in response to the Staff&#146;s comment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Principal Stockholders, page 158 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"><I>Please revise footnote 3 to identify the person(s) who have voting and investment power.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that it has revised page 160 in response to the Staff&#146;s comment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; (Deficit) Equity, page <FONT STYLE="white-space:nowrap">F-5</FONT></U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"><I>Tell us how you determined the reported amount of $9,764,000 for the redeemable convertible preferred stock at September</I><I></I><I>&nbsp;30, 2017. Also explain why additional paid in capital was increased by
$1,379,000 for the issuance of the redeemable preferred stock. Finally, tell us why accumulated deficit was reduced by $1,379,000 to arrive at a pro forma balance of $9,346,000 at September</I><I></I><I>&nbsp;30, 2017.</I> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><U>RESPONSE</U>: The Company advises the Staff that the reported amount of the redeemable convertible preferred stock at September&nbsp;30,
2017 of $9,764,000 reflects the fair value of the preferred stock at each transaction date, which was determined as follows: (i)&nbsp;in March 2017, the Company issued and sold 2,846,791 shares at $1.932 per share, or $5,500,000, which was reported
net of the fair value of the tranche rights liability of $2,014,000; (ii) in March 2017, the Company issued 2,587,992 shares in exchange for the license from Novartis valued at $1.22 per share, or $3,157,000; and (iii)&nbsp;in September 2017, the
Company issued and sold 2,329,193 shares for $1.932 per share but valued at $1.34 per share, or $3,121,000. The Company recorded the excess of the purchase price of $1.932 per share over the fair value of the preferred stock of $1.34 per share, or
$1,379,000, to additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital.</FONT></FONT> Finally, the accumulated deficit was reduced by $1,379,000 to arrive at a pro forma balance of $9,346,000 at
September&nbsp;30, 2017, because the Company assumed the sale and issuance of 4,792,716 shares of our Series A preferred stock in October 2017, which resulted in the elimination of the $1,379,000 tranche right liability at September&nbsp;30, 2017
through other income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Should you have any further comments or questions with regard to the foregoing, please contact the undersigned at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-570-1955.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Danielle M. Lauzon </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Danielle M. Lauzon </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosures </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top">Chen Schor<I>, resTORbio, Inc.</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mitchell S. Bloom, <I>Goodwin Procter LLP</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Peter N. Handrinos, <I>Latham</I><I></I><I>&nbsp;&amp; Watkins LLP</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nathan Ajiashvili, <I>Latham</I><I></I><I>&nbsp;&amp; Watkins LLP</I> </TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
